ADVL1414, A Phase 1 Study of Selinexor (KPT-330), a Selective XP01 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Sponsor: |
Children's Oncology Group |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ4204 |
U.S. Govt. ID: |
NCT02323880 |
Contact: |
Luca Szalontay, MD: 212-305-9770 / ls3399@cumc.columbia.edu |
We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects selinexor can cause; To learn more about the pharmacology (how your body handles the drug) of selinexor; To learn more about the biology of selinexor in blood and tumor tissue; To determine whether selinexor is a beneficial treatment for your tumor.
This study is closed
Investigator
Nobuko Hijiya, MD
Does your child have a solid tumor, including lymphoma and CNS tumors, or a glioma? |
Yes |
No |
Is your child between 12 months to 21 years of age? |
Yes |
No |
Has your child received a solid organ transplantation? |
Yes |
No |